Synlogic, Inc. (SYBX)
NASDAQ: SYBX · IEX Real-Time Price · USD
1.550
-0.050 (-3.13%)
At close: Jul 19, 2024, 4:30 PM
1.610
+0.060 (3.87%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Synlogic Revenue
Synlogic had revenue of $3.21M in the twelve months ending March 31, 2024, with 188.74% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $8.00K. In the year 2023, Synlogic had annual revenue of $3.37M with 185.68% growth.
Revenue (ttm)
$3.21M
Revenue Growth
+188.74%
P/S Ratio
5.66
Revenue / Employee
$534,167
Employees
6
Market Cap
18.15M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.37M | 2.19M | 185.68% |
Dec 31, 2022 | 1.18M | -574.00K | -32.73% |
Dec 31, 2021 | 1.75M | 1.21M | 221.83% |
Dec 31, 2020 | 545.00K | -1.68M | -75.49% |
Dec 31, 2019 | 2.22M | -296.00K | -11.75% |
Dec 31, 2018 | 2.52M | 76.00K | 3.11% |
Dec 31, 2017 | 2.44M | 2.00M | 450.45% |
Dec 31, 2016 | 444.00K | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cara Therapeutics | 16.94M |
Biotricity | 12.06M |
Aspira Women's Health | 8.99M |
Aeterna Zentaris | 2.37M |
Lyra Therapeutics | 1.68M |
Aptorum Group | 431.38K |
iBio, Inc. | 50.00K |
GlycoMimetics | 10.00K |
SYBX News
- 2 months ago - Synlogic Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewsWire
- 5 months ago - Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria - GlobeNewsWire
- 7 months ago - Synlogic Provides Corporate Update and Outlook for 2024 - GlobeNewsWire
- 7 months ago - Synlogic Announces Contract with the Air Force Research Lab - GlobeNewsWire
- 8 months ago - Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 - GlobeNewsWire